According to Palo Alto, California-based Atropos, its researchers have already come up with an initial AI model that has ...

Novartis AG said an experimental medicine helped patients with an autoimmune disease in late-stage studies, offering a boost ...

Novartis is partnering with Atropos Health to develop AI models that accelerate rare disease diagnosis, starting with a rare ...

The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

The drug, ianalumab, met its objectives in two Phase 3 studies in Sjögren’s syndrome, boosting the outlook of a ...

Novartis is hoping to gain approval for its Sjögren’s disease drug after it met the endpoints in two Phase III trials. The ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

The companies will develop AI models trained on real-world data to help identify and diagnose patients with paroxysmal nocturnal hemoglobinuria.

The Swiss government has met with senior executives from Roche (ROG: SIX) and Novartis (NOVN: VX) to discuss the outlook for ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...